LCM
DYN icon

Legato Capital Management’s Dyne Therapeutics DYN Stock Holding History

Legato Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42,665
Closed -$835K – 778
2025
Q4 		$835K Buy
+42,665
New +$808K 0.07% 403
2025
Q1 		– Sell
-12,960
Closed -$305K – 588
2024
Q4 		$305K Buy
+12,960
New +$383K 0.04% 493
2024
Q3 		– Sell
-15,480
Closed -$546K – 587
2024
Q2 		$546K Buy
15,480
+4,035
+35% +$117K 0.07% 419
2024
Q1 		$325K Buy
+11,445
New +$259K 0.04% 497

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Legato Capital Management's DYN Position: Q1 2026 in Review

Legato Capital Management sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 42,665 shares — an estimated $835K sold.

Legato Capital Management first reported a position in DYN in Q1 2024 and held it in 4 quarters. The position peaked at $835K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Legato Capital Management reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 42,665 Dyne Therapeutics shares in Q1 2026, an estimated $835K.
  • Legato Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and held it in 4 quarters.
  • Legato Capital Management's Dyne Therapeutics position peaked at $835K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.